Inhaled delivery of antiarrhythmic drugs potentially present a unique opportunity in the ability to deliver the drug straight to the heart via the lungs as a fast acting patient-administered medicine that then could quickly resolve disabling symptoms associated with Paroxysmal Atrial Fibrillation (>11.5 million global prevalence).
InCarda’s lead product candidate is InRhythm™, an inhaled version of a first line antiarrhythmic drug. InRhythm is designed to improve the pharmacokinetic (PK) profile of the antiarrhythmic, with the aim of enhancing efficacy without compromising the known safety and tolerability profile. Initial studies have shown rapid conversion of AF to normal sinus rhythm.
1Kim H Michael, Circulation Cardiovasc Qual Outcomes, May 2011